Now that Britain has grow to be the first western country to approve a Covid-19 shot, the highlight shifts to the high-stakes rollout. Vaccinating the country’s more or less 67 million people won’t happen overnight. The United Kingdom has ordered enough doses of the two-shot Pfizer-BioNTech vaccine to immunize 20 million people.
Click here for total coverage of Covid-19
Who will get the vaccine first?
The government plans to prioritize as it begins to deploy the vaccine, starting with residents and staff in care homes, then moving to people over 80 years old and health-care workers, documents show.
Britain will immunize people all the way through the wider population next, based on age and risk. The shot is expected to be to be had from next week.
Where can people get it?
In the United Kingdom, 50 hospitals are able to manage the vaccine, followed by doctors and pharmacists, assuming they have got the facilities needed to store the doses, Health Secretary Matt Hancock said on Sky News Wednesday.
The country has moved to expand the pool of people that can give the jabs beyond the National Health Service to other health professionals.
Where is the vaccine at the present time?
The vaccine is still at Pfizer’s production site in Puurs, Belgium. The United Kingdom’s Medicines and Healthcare Products Regulatory Agency said the doses will be made to be had starting next week.
Can I am getting a couple of vaccine?
Not for now. The United Kingdom only cleared the one made by Pfizer and BioNTech, even though a product the usage of a similar technology from Moderna Inc. might also get approved soon.
It’ll grow to be imaginable to mix shots when other vaccines are approved. That are supposed to work for shots that focus on the spike protein of SARS-CoV-2, according to Andrew Pollard, who is leading the University of Oxford’s vaccine trial with AstraZeneca Plc. The three front-runners use the spike protein as a target, as do many others in clinical tests.
Also Read | Bharat Biotech’s Covaxin: List of states which have started phase 3 trials of Covid-19 vaccine
How does the approved vaccine compare with others?
The product relies on a technology called messenger RNA, which has never been used to make approved vaccines before. So does Moderna’s. Both showed they were more than 90% effective in clinical trials. The approach is designed to change into the body’s own cells into vaccine-making factories.
The main difference is that the Pfizer-BioNTech product will have to be stored ultra-cold until a couple of days before it is used. Moderna’s vaccine is steady at refrigerator temperatures for 30 days. Astra-Oxford’s jab importantly may also be kept at refrigerator temperatures.
How do we realize the vaccine is secure?
Pfizer and BioNTech tested the product in a clinical trial involving nearly 44,000 people without observing severe side effects. The most typical symptoms were fatigue and headaches.
The United Kingdom regulator, the Medicines and Healthcare Products Regulatory Agency, said on Wednesday that the vaccine “met its strict standards of safety, quality and effectiveness.” Hancock described the review as having been “rigorous,” not rushed.
Monitoring safety will be probably the most biggest challenges once shots are rolled out widely, Emer Cooke, the new head of the European Medicines Agency, said in an interview final month.[ad_2]